University Library
  • Login
A gateway to Melbourne's research publications
Minerva Access is the University's Institutional Repository. It aims to collect, preserve, and showcase the intellectual output of staff and students of the University of Melbourne for a global audience.
View Item 
  • Minerva Access
  • Medicine, Dentistry & Health Sciences
  • Medical Biology
  • Medical Biology - Research Publications
  • View Item
  • Minerva Access
  • Medicine, Dentistry & Health Sciences
  • Medical Biology
  • Medical Biology - Research Publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

    BCL-2 is dispensable for thrombopoiesis and platelet survival

    Thumbnail
    Download
    Published version (2.004Mb)

    Citations
    Scopus
    Altmetric
    35
    Author
    Debrincat, MA; Pleines, I; Lebois, M; Lane, RM; Holmes, ML; Corbin, J; Vandenberg, CJ; Alexander, WS; Ng, AP; Strasser, A; ...
    Date
    2015-04-01
    Source Title
    Cell Death and Disease
    Publisher
    NATURE PUBLISHING GROUP
    University of Melbourne Author/s
    Josefsson, Emma; Kile, Benjamin; Strasser, Andreas; Ng, Ashley; Vandenberg, Cassandra; Bouillet, Philippe; Alexander, Warren; DEBRINCAT, MARLYSE ANNE; PLEINES, IRINA
    Affiliation
    Medical Biology (W.E.H.I.)
    School of BioSciences
    Metadata
    Show full item record
    Document Type
    Journal Article
    Citations
    Debrincat, M. A., Pleines, I., Lebois, M., Lane, R. M., Holmes, M. L., Corbin, J., Vandenberg, C. J., Alexander, W. S., Ng, A. P., Strasser, A., Bouillet, P., Sola-Visner, M., Kile, B. T. & Josefsson, E. C. (2015). BCL-2 is dispensable for thrombopoiesis and platelet survival. CELL DEATH & DISEASE, 6 (4), https://doi.org/10.1038/cddis.2015.97.
    Access Status
    Open Access
    URI
    http://hdl.handle.net/11343/260182
    DOI
    10.1038/cddis.2015.97
    Abstract
    Navitoclax (ABT-263), an inhibitor of the pro-survival BCL-2 family proteins BCL-2, BCL-XL and BCL-W, has shown clinical efficacy in certain BCL-2-dependent haematological cancers, but causes dose-limiting thrombocytopaenia. The latter effect is caused by Navitoclax directly inducing the apoptotic death of platelets, which are dependent on BCL-XL for survival. Recently, ABT-199, a selective BCL-2 antagonist, was developed. It has shown promising anti-leukaemia activity in patients whilst sparing platelets, suggesting that the megakaryocyte lineage does not require BCL-2. In order to elucidate the role of BCL-2 in megakaryocyte and platelet survival, we generated mice with a lineage-specific deletion of Bcl2, alone or in combination with loss of Mcl1 or Bclx. Platelet production and platelet survival were analysed. Additionally, we made use of BH3 mimetics that selectively inhibit BCL-2 or BCL-XL. We show that the deletion of BCL-2, on its own or in concert with MCL-1, does not affect platelet production or platelet lifespan. Thrombocytopaenia in Bclx-deficient mice was not affected by additional genetic loss or pharmacological inhibition of BCL-2. Thus, BCL-2 is dispensable for thrombopoiesis and platelet survival in mice.

    Export Reference in RIS Format     

    Endnote

    • Click on "Export Reference in RIS Format" and choose "open with... Endnote".

    Refworks

    • Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References


    Collections
    • Minerva Elements Records [52369]
    • School of BioSciences - Research Publications [1504]
    • Medical Biology - Research Publications [1412]
    Minerva AccessDepositing Your Work (for University of Melbourne Staff and Students)NewsFAQs

    BrowseCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects
    My AccountLoginRegister
    StatisticsMost Popular ItemsStatistics by CountryMost Popular Authors